Ikena Oncology Pre-Tax Profit Margin 2021-2025 | IMA
Ikena Oncology pre-tax profit margin from 2021 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Ikena Oncology Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2023-12-31 |
$0.01B |
$-0.07B |
-755.56% |
| 2023-09-30 |
$0.01B |
$-0.06B |
-476.92% |
| 2023-06-30 |
$0.02B |
$-0.06B |
-344.44% |
| 2023-03-31 |
$0.02B |
$-0.07B |
-406.25% |
| 2022-12-31 |
$0.01B |
$-0.07B |
-485.71% |
| 2022-09-30 |
$0.03B |
$-0.05B |
-175.86% |
| 2022-06-30 |
$0.03B |
$-0.05B |
-181.48% |
| 2022-03-31 |
$0.03B |
$-0.04B |
-135.48% |
| 2021-12-31 |
$0.03B |
$-0.04B |
-112.90% |
| 2021-09-30 |
$0.01B |
$-0.06B |
-581.82% |
| 2021-06-30 |
$0.01B |
$-0.06B |
-550.00% |
| 2021-03-31 |
$0.01B |
$-0.05B |
-522.22% |
| 2020-12-31 |
$0.01B |
$-0.04B |
-488.89% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.072B |
$0.009B |
|
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.
|
